From the Journals

CSF Proteomics Identifies New Biomarkers for Multiple Sclerosis

Large-cohort CSF proteomics from the Mann Lab identifies a 22-protein panel distinguishing MS from related diseases

  • By

  • March 11, 2026

  • 3 min

Share

  • 1

    Study identifies a 22-protein panel for MS diagnosis.

  • 2

    Utilizes mass spectrometry to analyze CSF.

  • 3

    Addresses challenges in patients without classical biomarkers.

  • 4

    Analyzes over 5,000 neurological disorder patients.

  • 5

    Provides insights into long-term disability outcomes.

  • 6

    Potential applications to other neurological diseases.

Original Source(s)

CSF Proteomics Identifies New Biomarkers for Multiple Sclerosis

Large-cohort CSF proteomics from the Mann Lab identifies a 22-protein panel distinguishing MS from related diseases

  • March 11, 2026

  • 3 min

Related Content

Sudden Vision Loss: Could It Be Pituitary Apoplexy?

Case report highlights delayed treatment and persistent visual loss in a patient with pituitary adenoma

FDA Approves Therapy for Cerebral Folate Deficiency

Decision addresses a rare neurologic disorder linked to folate transport impairment.

Blood Test Forecasts Alzheimer's Onset

Plasma p-tau217 “clocks” estimate timing of symptoms years before clinical diagnosis

  • March 9, 2026

  • 2 min